Of the patients receiving anti-TNF-α therapy, RA was noted in 30 (43.5%), ankylosing spondylitis in 29 (42%), psoriatic arthritis in 7 (10.1%), and Behçet's disease in 3 (4.3%). This evidence concerns the gene TNF and ankylosing spondylitis.